◆ TICKERBASEOpen interactive view →
◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY
Home › All stocks › I › IMTX

Immatics NV (IMTX) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-09-15

Immatics NV (IMTX) operates in the BIOTECHNOLOGY industry and is headquartered in Tübingen, Germany with about 704 employees. Its market capitalization is roughly $1 billion. In the fiscal year ended 2025-12-31, IMTX reported €48M in revenue and (€196M) in net income.

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States.

Interactive charts & full statements → Open the IMTX valuation workbench →

IMTX Revenue & Earnings History — Annual Income Statement

Income statementTTM → 2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Total Revenue€42M€48M€156M€54M€173M€35M€31M€18M€4M
Gross Profit€42M€48M€156M€54M€173M€35M(€36M)(€22M)(€30M)
Gross Margin %100.0%100.0%100.0%100.0%100.0%100.0%-114.7%-117.3%-801.1%
Operating Income (EBIT)(€227M)(€182M)(€39M)(€102M)€30M(€86M)(€70M)(€33M)(€34M)
Operating Margin %-543.8%-377.1%-24.8%-188.4%17.3%-248.2%-223.1%-178.9%-912.7%
Net Income(€207M)(€196M)€15M(€95M)€28M(€93M)(€211M)(€32M)(€31M)
Net Margin %-495.3%-407.0%9.8%-175.3%16.0%-268.5%-676.0%-172.0%-834.1%
EBITDA(€194M)(€185M)€34M(€89M)€50M(€88M)(€67M)(€28M)(€32M)
Earnings Per Share (EPS)€-1.59€-1.61€0.14€-1.18€0.41€-1.48€-4.40€-0.50€-0.50
Shares Outstanding (M)137M122M107M81M68M63M48M63M63M

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

IMTX Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Total Revenue€9M€8M€20M€5M€5M€19M€56M€51M
Gross Profit€9M€8M€20M€5M€5M€19M€56M€51M
Gross Margin %100.0%100.0%100.0%100.0%100.0%100.0%100.0%100.0%
Operating Income (EBIT)(€67M)(€66M)(€39M)(€55M)(€53M)(€35M)€1M€1M
Operating Margin %-735.0%-867.9%-196.8%-1053.3%-1121.5%-190.4%1.6%1.0%
Net Income(€62M)(€58M)(€36M)(€51M)(€70M)(€40M)€45M(€9M)
Net Margin %-683.4%-759.5%-180.7%-974.5%-1485.1%-214.5%79.8%-17.0%
EBITDA(€60M)(€55M)(€32M)(€47M)(€68M)(€37M)€47M€1M
Earnings Per Share (EPS)€-0.46€-0.43€-0.28€-0.42€-0.58€-0.33€0.42€-0.08
Shares Outstanding (M)137M135M126M122M122M122M107M110M

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

IMTX Free Cash Flow History

Cash flowTTM → 2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Cash from Operations (CFO)(€206M)(€170M)(€158M)€18M€100M(€82M)(€86M)€71M€21M
Capital Expenditures (CapEx)€4M€6M€16M€31M€6M€6M€8M€2M€1M
Free Cash Flow (FCF)(€210M)(€176M)(€175M)(€13M)€94M(€87M)(€93M)€69M€20M
FCF Margin %-503.4%-364.6%-112.0%-23.6%54.3%-251.5%-298.0%372.6%535.2%

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

IMTX Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Cash from Operations (CFO)(€61M)(€43M)(€58M)(€45M)(€39M)(€34M)(€58M)(€34M)
Capital Expenditures (CapEx)€1M€1M€1M€1M€2M€3M€2M€3M
Free Cash Flow (FCF)(€62M)(€44M)(€59M)(€46M)(€41M)(€37M)(€60M)(€37M)
FCF Margin %-678.9%-571.6%-296.4%-882.7%-857.4%-201.0%-107.0%-72.2%

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

IMTX Balance Sheet History

Balance sheet2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Total Assets€486M€562M€696M€510M€408M€175M€255M€134M€61M
Cash & Cash Equivalents€232M€346M€237M€218M€149M€133M€208M€103M€39M
Total Liabilities€86M€78M€121M€292M€204M€151M€167M€175M€70M
Total Debt (Short + Long-Term)€3M€3M€3M€3M€2M€3M€2M€1M€0M
Total Shareholders' Equity€399M€484M€575M€218M€203M€24M€87M(€42M)(€10M)

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive IMTX viewer.

Other Companies in BIOTECHNOLOGY

← IMTMAll “I” companiesIMUX →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.